» Articles » PMID: 32726803

Papain-like Protease Regulates SARS-CoV-2 Viral Spread and Innate Immunity

Abstract

The papain-like protease PLpro is an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread. PLpro is also implicated in cleaving proteinaceous post-translational modifications on host proteins as an evasion mechanism against host antiviral immune responses. Here we perform biochemical, structural and functional characterization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PLpro (SCoV2-PLpro) and outline differences with SARS-CoV PLpro (SCoV-PLpro) in regulation of host interferon and NF-κB pathways. SCoV2-PLpro and SCoV-PLpro share 83% sequence identity but exhibit different host substrate preferences; SCoV2-PLpro preferentially cleaves the ubiquitin-like interferon-stimulated gene 15 protein (ISG15), whereas SCoV-PLpro predominantly targets ubiquitin chains. The crystal structure of SCoV2-PLpro in complex with ISG15 reveals distinctive interactions with the amino-terminal ubiquitin-like domain of ISG15, highlighting the high affinity and specificity of these interactions. Furthermore, upon infection, SCoV2-PLpro contributes to the cleavage of ISG15 from interferon responsive factor 3 (IRF3) and attenuates type I interferon responses. Notably, inhibition of SCoV2-PLpro with GRL-0617 impairs the virus-induced cytopathogenic effect, maintains the antiviral interferon pathway and reduces viral replication in infected cells. These results highlight a potential dual therapeutic strategy in which targeting of SCoV2-PLpro can suppress SARS-CoV-2 infection and promote antiviral immunity.

Citing Articles

Anti-interferon armamentarium of human coronaviruses.

Khatun O, Kaur S, Tripathi S Cell Mol Life Sci. 2025; 82(1):116.

PMID: 40074984 PMC: 11904029. DOI: 10.1007/s00018-025-05605-z.


9-aminominocycline potentiates the efficacy of EIDD-1931 and PF-332 by targeting the papain like protease enzyme of SARS-CoV-2.

Pandey K, Lewis D, Heo K, Acharya A, Fields T, Gowda K Sci Rep. 2025; 15(1):5671.

PMID: 39955340 PMC: 11830066. DOI: 10.1038/s41598-025-89717-3.


Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.

Jadhav P, Liang X, Ansari A, Tan B, Tan H, Li K Nat Commun. 2025; 16(1):1604.

PMID: 39948104 PMC: 11825904. DOI: 10.1038/s41467-025-56902-x.


Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.

Varghese A, Liu J, Liu B, Guo W, Dong F, Patterson T Molecules. 2025; 30(3).

PMID: 39942596 PMC: 11820935. DOI: 10.3390/molecules30030491.


Regulation of viral replication by host restriction factors.

Lin Y, Zhu Y, Jing L, Lei X, Xie Z Front Immunol. 2025; 16:1484119.

PMID: 39917304 PMC: 11798991. DOI: 10.3389/fimmu.2025.1484119.


References
1.
Sali A, Blundell T . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234(3):779-815. DOI: 10.1006/jmbi.1993.1626. View

2.
Sheikh F, Dickensheets H, Gamero A, Vogel S, Donnelly R . An essential role for IFN-β in the induction of IFN-stimulated gene expression by LPS in macrophages. J Leukoc Biol. 2014; 96(4):591-600. PMC: 4163629. DOI: 10.1189/jlb.2A0414-191R. View

3.
Niemeyer D, Mosbauer K, Klein E, Sieberg A, Mettelman R, Mielech A . The papain-like protease determines a virulence trait that varies among members of the SARS-coronavirus species. PLoS Pathog. 2018; 14(9):e1007296. PMC: 6171950. DOI: 10.1371/journal.ppat.1007296. View

4.
Sommer S, Weikart N, Linne U, Mootz H . Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol-alkyne addition. Bioorg Med Chem. 2013; 21(9):2511-7. DOI: 10.1016/j.bmc.2013.02.039. View

5.
Piana S, Donchev A, Robustelli P, Shaw D . Water dispersion interactions strongly influence simulated structural properties of disordered protein states. J Phys Chem B. 2015; 119(16):5113-23. DOI: 10.1021/jp508971m. View